MorphoSys Presents Early Felzartamab Data From Autoimmune Kidney Disease Trial

  • MorphoSys AG MOR presented interim results from the M-PLACE Phase 1b/2a study with felzartamab at the 2021 Annual Meeting of the American Society of Nephrology (ASN).
  • Felzartamab is a fully human IgG1 monoclonal anti-CD38 antibody that can potentially deplete CD38-positive plasma cells that produce and secrete destructive autoantibodies. 
  • Depleting those plasma cells could be effective in the treatment of anti-PLA2R antibody-positive Membranous Nephropathy (MN).
  • Of the 27 treated patients with evaluable results, 24 showed an initial rapid reduction of anti-PLA2R antibody levels one week after the first treatment. 
  • After 12 weeks of treatment, most patients showed a substantial reduction in autoantibody titer. 
  • An early assessment of urine protein at six months of treatment showed a decrease in 6 of 10 patients, with four patients having a reduction of more than 50% from baseline. 
  • Primary membranous nephropathy (MN) is a rare autoimmune kidney disease and a leading cause of nephrotic syndrome. 
  • In 2017, MorphoSys entered into an exclusive regional licensing agreement with I-Mab IMAB to develop and commercialize Felzartamab in Greater China. 
  • Price Action: MOR shares are down 1.94% at $11.63 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsKidney DiseasesPhase 1 TrialPhase 2 TrialRare Kidney Diseases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!